Viromed Medical AG, a medical technology company specializing in cold plasma technology, has entered into a global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH to commercialize the PulmoPlas® technology for veterinary applications. The collaboration grants NEBU-TEC exclusive worldwide distribution rights for veterinary uses, combining Viromed's cold plasma technology with NEBU-TEC's nebulization devices.
The partnership aims to address respiratory diseases in animals, starting with pulmonary conditions in horses. According to the companies, respiratory diseases affect a substantial proportion of the equine population, particularly in the European equine market and equestrian sports, creating significant demand for effective solutions. The market launch of PulmoPlas® vet is scheduled for later in 2026, and no regulatory approval is required for veterinary use.
Viromed's cold plasma technology has previously been applied in human medicine, but this partnership marks a strategic expansion into veterinary medicine. Uwe Perbandt, CEO of Viromed Medical AG, stated: "The partnership with NEBU-TEC represents an important step in the international commercialization of our PulmoPlas® platform. Combining our cold plasma technology with NEBU-TEC's nebulization expertise opens up new fields of application in veterinary medicine and, going forward, also for applications in human medicine."
The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which also paves the way for future human applications of the combined technology. Eike Kern, Managing Director of NEBU-TEC, emphasized: "The combination of inhalative application and cold plasma opens up new therapeutic possibilities. By bringing together complementary technologies, we are creating innovative and safe concepts for the treatment of both animals and humans – effective, safe and forward-looking."
NEBU-TEC, a globally active medical technology company with 30 years of experience in aerosol medicine, develops and manufactures inhalation devices for both human and veterinary medicine. The company's expertise in nebulization technology will be integral to delivering PulmoPlas® as an inhaled therapy.
For Viromed, this agreement builds on its strategy of expanding partnerships to commercialize cold plasma technology internationally. The company, listed on the stock exchange since October 2022, focuses on medical applications of cold plasma through its subsidiary Viromed Medical GmbH. By entering the veterinary market, Viromed expects to tap into attractive market potential while laying the groundwork for future human medical applications.
The implications of this announcement are significant for both the veterinary and medical technology industries. If successful, the combination of cold plasma and inhalation therapy could offer a novel, non-invasive treatment option for respiratory diseases in animals, potentially improving outcomes and reducing reliance on antibiotics. Additionally, the partnership sets the stage for similar applications in human medicine, as the devices already meet MDR requirements for human use. This could eventually lead to new therapies for respiratory conditions in humans, broadening the impact of cold plasma technology beyond its current applications.
More information about Viromed Medical AG can be found at www.viromed-medical-ag.de and about NEBU-TEC at www.nebu-tec.de.
